Startup Scout 3 Aug 2018 This Biotech Targets the Neuronal Causes of Hearing Loss Today, we’re in Archamps, France, visiting Pragma Therapeutics, a neuroscience biotech developing drugs to regulate neuronal signalling in hearing loss. Mission: Pragma Therapeutics develops treatments for noise-induced and age-related hearing loss that regulate glutamate levels. Glutamate is the most abundant neurotransmitter in the nervous system and makes nerve cells turn on, or fire. In patients with […] August 3, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 23 Jul 2018 Sangamo Acquires French Biotech to Develop CAR-T Therapies for Autoimmune Disease Sangamo Therapeutics has acquired TxCell with a view to utilizing its CAR-T technology to prevent organ transplant rejections and treat autoimmune disease. Sangamo, based in California, is known for bringing the first in-vivo gene therapy to the market. The company entered into an agreement to purchase TxCell for €72M. Sangamo plans to combine its zinc […] July 23, 2018 - 3 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 13 Jul 2018 French Biotech Raises €12.5M for Antibiotic Booster Drugs French-biotech Antabio closed €12.5M at series A to fund its pipeline of antibiotic booster drugs that should help in the global fight against antimicrobial resistance. After raising €7.3M last year, Antabio extended its Series A financing round with €5.2M of additional funding raised from private investors. The French biotech will use the funding to continue […] July 13, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jul 2018 Gene Therapy for Retinitis Pigmentosa Tested in Humans for the First Time French biotech Horama has treated the first patients with a gene therapy for retinitis pigmentosa that could prevent the progressive loss of vision caused by this genetic condition. A Phase I/II trial with Horama’s gene therapy for retinitis pigmentosa is running at the Nantes University Hospital. The therapy is aimed at fixing genetic defects in a […] July 11, 2018 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 5 Jul 2018 Series A Round Could Bring French Microbiome Treatment for Bowel Disease Into the Clinic Netbiotix has raised €7.5M to bring its lead candidate for inflammatory bowel disease into clinical trials. The treatment uses a bacterium found in the gut to prevent and dampen inflammation. The company, based in Paris, develops treatments for inflammatory bowel disease (IBD) that consist of a single microbial strain that interacts with cells in the […] July 5, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
More News! 2 Jul 2018 New Blood Test Brings Cheaper Hepatitis B Diagnosis European and African researchers are developing a hepatitis B blood test that could help identify patients in Africa’s poorest regions who need immediate treatment. While treatments for hepatitis B are now available at a low cost, managing treatments effectively is still a challenge in Africa. This is because some patients who are infected with the […] July 2, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
Startup Scout 29 Jun 2018 This French Biotech Links Drugs Together to Target Bone Cancer This week, we’re in Aronnax, France, visiting Atlanthera, a biotech developing more effective treatments for bone cancer using a two-compound approach. Mission: Antlanthera was founded in 2011 with the goal of developing more effective drugs for bone cancer. The company uses biophosphonates, a popular bone-building treatment for osteoporosis, to target bone tissue. Atlanthera’s technology works […] June 29, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 5 Jun 2018 French Biotech Raises €40M to Fight Hepatitis B and NASH Enyo Pharma has completed a Series B financing round to start Phase II trials by the end of this year testing its lead compound in two different forms of liver disease. Enyo Pharma, based in Lyon, has raised €40M from OrbiMed and other investors to start two Phase II trials testing its lead drug candidate […] June 5, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 29 May 2018 This Immunotherapy Could Be The First to Treat Milk Allergy in Children DBV Technologies has shown in a Phase II trial that its skin patch could desensitize over 60% of children with strong milk allergy. DBV Technologies, one of the largest public biotechs in France, is developing a skin patch technology to treat several forms of food allergies. The company has released new, promising data on its milk […] May 29, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Interview 24 May 2018 Sugar-Munching Microbes Put the ‘Eco’ into the Dyeing Industry The commercial dyeing industry is not known for being eco-friendly, which is something that PILI – a synbio startup based in France – is hoping to address with their color producing microbes. Philip chatted with its CEO, Jeremie Blache, to find out more about the company, its recent successful fundraising round and how its technology […] May 24, 2018 - 5 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
Startup Scout 18 May 2018 This French Biotech Targets Retinal Cells to Treat Blindness Today, we’re in Paris, visiting SparingVision, a biotech trying to combat blindness using a protein that slows down the degeneration of cone cells in the retina. Mission: SparingVision uses a naturally occurring protein called rod-derived cone-viability factor, which binds to a transmembrane peptide on cone photoreceptor cells in the retina and allows more glucose to enter […] May 18, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
More News! 17 May 2018 After settling lawsuit with Bayer, Cellectis spin-off launches €41M follow-on offering Cellectis spin-off Calyxt has launched a €41M follow-on round after settling the lawsuit it recently brought against Bayer CropScience, for breach of a license agreement for access to patents for its TALEN technology. The French biotech Cellectis owns 79.1% of the ag biotech’s outstanding shares. Cellectis is well-known for its gene editing tool TALEN. However, while it focuses […] May 17, 2018 - 2 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email